BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bichoupan K, Martel-Laferriere V, Sachs D, Ng M, Schonfeld EA, Pappas A, Crismale J, Stivala A, Khaitova V, Gardenier D, Linderman M, Perumalswami PV, Schiano TD, Odin JA, Liu L, Moskowitz AJ, Dieterich DT, Branch AD. Costs of telaprevir-based triple therapy for hepatitis C: $189,000 per sustained virological response. Hepatology 2014;60:1187-95. [PMID: 25065814 DOI: 10.1002/hep.27340] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 3.6] [Reference Citation Analysis]
Number Citing Articles
1 Stahmeyer JT, Krauth C, Bert F, Pfeiffer-Vornkahl H, Alshuth U, Hüppe D, Mauss S, Rossol S. Costs and outcomes of treating chronic hepatitis C patients in routine care - results from a nationwide multicenter trial. J Viral Hepat 2016;23:105-15. [PMID: 26411532 DOI: 10.1111/jvh.12471] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
2 Klepper A, Eng FJ, Doyle EH, El-Shamy A, Rahman AH, Fiel MI, Avino GC, Lee M, Ye F, Roayaie S, Bansal MB, MacDonald MR, Schiano TD, Branch AD. Hepatitis C virus double-stranded RNA is the predominant form in human liver and in interferon-treated cells. Hepatology 2017;66:357-70. [PMID: 27642141 DOI: 10.1002/hep.28846] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
3 Chamorro-de-vega E, Gimenez-manzorro A, Rodriguez-gonzalez CG, Escudero-vilaplana V, Collado Borrell R, Ibañez-garcia S, Lallana Sainz E, Lobato Matilla E, Lorenzo-pinto A, Manrique-rodriguez S, Fernandez-llamazares CM, Marzal-alfaro M, Ribed A, Romero Jimenez RM, Sarobe Gonzalez C, Herranz A, Sanjurjo M. Effectiveness and Safety of Ombitasvir-Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin for HCV Genotype 1 Infection for 12 Weeks Under Routine Clinical Practice. Ann Pharmacother 2016;50:901-8. [DOI: 10.1177/1060028016659306] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
4 Piekarska A, Koślińska-Berkan E, Wójcik K, Skubała A, Jabłkowski M, Deroń Z, Berkan-Kawińska A. Efficacy and direct costs of chronic hepatitis C treatment with first generation NS3/4A protease inhibitors in a real life population. Clin Exp Hepatol 2016;2:133-7. [PMID: 28856277 DOI: 10.5114/ceh.2016.63869] [Reference Citation Analysis]
5 Maan R, Zaim R, van der Meer AJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, Manns MP, Zeuzem S, Hansen BE, Janssen H, Veldt BJ, de Knegt RJ, Uyl-de Groot CA. Real-world medical costs of antiviral therapy among patients with chronic HCV infection and advanced hepatic fibrosis. J Gastroenterol Hepatol 2016;31:1851-9. [PMID: 26990109 DOI: 10.1111/jgh.13373] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
6 Castro R, Perazzo H, Grinsztejn B, Veloso VG, Hyde C. Chronic Hepatitis C: An Overview of Evidence on Epidemiology and Management from a Brazilian Perspective. Int J Hepatol. 2015;2015:852968. [PMID: 26693356 DOI: 10.1155/2015/852968] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
7 Pfeil AM, Reich O, Guerra IM, Cure S, Negro F, Müllhaupt B, Lavanchy D, Schwenkglenks M. Cost-effectiveness analysis of sofosbuvir compared to current standard treatment in Swiss patients with chronic hepatitis C. PLoS One 2015;10:e0126984. [PMID: 25974722 DOI: 10.1371/journal.pone.0126984] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 4.4] [Reference Citation Analysis]
8 Stahmeyer JT, Rossol S, Krauth C. Outcomes, costs and cost-effectiveness of treating hepatitis C with direct acting antivirals. J Comp Eff Res 2015;4:267-77. [PMID: 25960028 DOI: 10.2217/cer.15.13] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
9 Barclay ST, Cooke GS, Holtham E, Gauthier A, Schwarzbard J, Atanasov P, Irving WL; HCV Research UK. A new paradigm evaluating cost per cure of HCV infection in the UK. Hepatol Med Policy 2016;1:2. [PMID: 30288304 DOI: 10.1186/s41124-016-0002-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
10 Woodrell C, Weiss J, Branch A, Gardenier D, Krauskopf K, Kil N, Paredes H, Bichoupan K, Sigel K. Primary Care-Based Hepatitis C Treatment Outcomes With First-Generation Direct-Acting Agents. J Addict Med 2015;9:405-10. [PMID: 26291545 DOI: 10.1097/ADM.0000000000000147] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
11 Bach TA, Zaiken K. Outcomes of treatment with direct-acting antivirals for infection with hepatitis C virus genotypes 1-4 in an ambulatory care setting. Am J Health Syst Pharm 2017;74:S1-9. [PMID: 28213381 DOI: 10.2146/ajhp160567] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
12 Younossi ZM, Park H, Dieterich D, Saab S, Ahmed A, Gordon SC. Assessment of cost of innovation versus the value of health gains associated with treatment of chronic hepatitis C in the United States: The quality-adjusted cost of care. Medicine (Baltimore) 2016;95:e5048. [PMID: 27741116 DOI: 10.1097/MD.0000000000005048] [Cited by in Crossref: 27] [Cited by in F6Publishing: 9] [Article Influence: 5.4] [Reference Citation Analysis]
13 Vernaz N, Girardin F, Goossens N, Brügger U, Riguzzi M, Perrier A, Negro F. Drug Pricing Evolution in Hepatitis C. PLoS One 2016;11:e0157098. [PMID: 27310294 DOI: 10.1371/journal.pone.0157098] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
14 Sarpel D, Baichoo E, Dieterich DT. Chronic hepatitis B and C infection in the United States: a review of current guidelines, disease burden and cost effectiveness of screening. Expert Review of Anti-infective Therapy 2016;14:511-21. [DOI: 10.1586/14787210.2016.1174066] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
15 Kanwal F, El-Serag HB, Ross D. Surveillance for hepatocellular carcinoma: can we focus on the mission? Clin Gastroenterol Hepatol 2015;13:805-7. [PMID: 25541193 DOI: 10.1016/j.cgh.2014.12.016] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
16 Okafor PN, Chiejina M, de Pretis N, Talwalkar JA. Secondary analysis of large databases for hepatology research. Journal of Hepatology 2016;64:946-56. [DOI: 10.1016/j.jhep.2015.12.019] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
17 Ueda Y, Dansako H, Satoh S, Kim HS, Wataya Y, Doi H, Ikeda M, Kato N. Evaluation of preclinical antimalarial drugs, which can overcome direct-acting antivirals-resistant hepatitis C viruses, using the viral reporter assay systems. Virus Res 2017;235:37-48. [PMID: 28322919 DOI: 10.1016/j.virusres.2017.03.015] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
18 Bichoupan K, Tandon N, Crismale JF, Hartman J, Del Bello D, Patel N, Chekuri S, Harty A, Ng M, Sigel KM, Bansal MB, Grewal P, Chang CY, Leong J, Im GY, Liu LU, Odin JA, Bach N, Friedman SL, Schiano TD, Perumalswami PV, Dieterich DT, Branch AD. Real-world cure rates for hepatitis C virus treatments that include simeprevir and/or sofosbuvir are comparable to clinical trial results. World J Virol 2017; 6(4): 59-72 [PMID: 29147645 DOI: 10.5501/wjv.v6.i4.59] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
19 Iyengar S, Tay-Teo K, Vogler S, Beyer P, Wiktor S, de Joncheere K, Hill S. Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis. PLoS Med 2016;13:e1002032. [PMID: 27243629 DOI: 10.1371/journal.pmed.1002032] [Cited by in Crossref: 158] [Cited by in F6Publishing: 128] [Article Influence: 26.3] [Reference Citation Analysis]
20 Cenderello G, Fanizza C, Marenco S, Nicolini LA, Artioli S, Baldissarro I, Dentone C, De Leo P, Di Biagio A. Cost per care of the first year of direct antiviral agents in the Liguria Region: a multicenter analysis. Clinicoecon Outcomes Res 2017;9:281-93. [PMID: 28579812 DOI: 10.2147/CEOR.S129859] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
21 Aghemo A, Donato MF. Sofosbuvir treatment in the pre and post liver transplantation phase: the sooner, the better. Gastroenterology. 2015;148:13-16. [PMID: 25451651 DOI: 10.1053/j.gastro.2014.11.025] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
22 Gardenier D, Kwong J, Olson MC, Epstein R. Epidemiology, Screening, and Pretreatment Evaluation of the Patient With Chronic Hepatitis C Infection. The Journal for Nurse Practitioners 2015;11:109-15. [DOI: 10.1016/j.nurpra.2014.10.015] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
23 Karmarkar T, Rodriguez-Watson CV, Watson E, Zheng H, Gaskin DJ, Padula WV. Value of Triage Treatment Strategies to Distribute Hepatitis C Direct-Acting Antiviral Agents in an Integrated Healthcare System: A Cost-Effectiveness Analysis. Value Health 2022:S1098-3015(22)00145-0. [PMID: 35484030 DOI: 10.1016/j.jval.2022.03.003] [Reference Citation Analysis]
24 Smyth D, Webster D. Hepatitis C: pay now or pay later? Future Virology 2015;10:1285-90. [DOI: 10.2217/fvl.15.104] [Reference Citation Analysis]
25 Li HC, Lo SY. Hepatitis C virus: Virology, diagnosis and treatment. World J Hepatol 2015; 7(10): 1377-1389 [PMID: 26052383 DOI: 10.4254/wjh.v7.i10.1377] [Cited by in Crossref: 76] [Cited by in F6Publishing: 52] [Article Influence: 10.9] [Reference Citation Analysis]
26 Yeh ML, Hsieh MY, Huang CI, Huang CF, Hsieh MH, Liang PC, Lin YH, Hou NJ, Lin ZY, Chen SC. Personalized Therapy of Chronic Hepatitis C and B Dually Infected Patients With Pegylated Interferon Plus Ribavirin: A Randomized Study. Medicine (Baltimore). 2015;94:e1837. [PMID: 26496327 DOI: 10.1097/md.0000000000001837] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
27 Walker DR, Pedrosa MC, Manthena SR, Patel N, Marx SE. Early View of the Effectiveness of New Direct-Acting Antiviral (DAA) Regimens in Patients with Hepatitis C Virus (HCV). Adv Ther 2015;32:1117-27. [PMID: 26538232 DOI: 10.1007/s12325-015-0258-5] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
28 Tsai SM, Kao JT, Tsai YF. How hepatitis C patients manage the treatment process of pegylated interferon and ribavirin therapy: a qualitative study. BMC Health Serv Res 2016;16:247. [PMID: 27402141 DOI: 10.1186/s12913-016-1503-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
29 Craxì L, Cammà C, Craxì A. HCV: the best cure possible or the best possible cure? J Viral Hepat 2015;22:627-9. [PMID: 26135025 DOI: 10.1111/jvh.12411] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
30 Shafran SD. The hepatitis C genotype 1 paradox: cost per treatment is increasing, but cost per cure is decreasing. Can J Gastroenterol Hepatol 2015;29:46-8. [PMID: 25706574 DOI: 10.1155/2015/216395] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
31 Judge CJ, Kostadinova L, Sherman KE, Butt AA, Falck-Ytter Y, Funderburg NT, Landay AL, Lederman MM, Sieg SF, Sandberg JK, Anthony DD. CD56bright NK IL-7Rα expression negatively associates with HCV level, and IL-7-induced NK function is impaired during HCV and HIV infections. J Leukoc Biol 2017;102:171-84. [PMID: 28400540 DOI: 10.1189/jlb.5A1116-456R] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
32 Sethi N, Tapper EB, Vong A, Sethi S, Rourke M, Afdhal NH. Direct costs of first-generation protease inhibitors for the treatment of genotype 1 chronic hepatitis C viral infection. J Viral Hepat 2015;22:974-6. [PMID: 26010946 DOI: 10.1111/jvh.12421] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
33 Stahmeyer JT, Rossol S, Bert F, Böker KH, Bruch HR, Eisenbach C, Link R, John C, Mauss S, Heyne R, Schott E, Pfeiffer-Vornkahl H, Hüppe D, Krauth C. Outcomes and Costs of Treating Hepatitis C Patients in the Era of First Generation Protease Inhibitors - Results from the PAN Study. PLoS One 2016;11:e0159976. [PMID: 27467772 DOI: 10.1371/journal.pone.0159976] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
34 Mattingly TJ 2nd, Love BL, Khokhar B. Real World Cost-of-Illness Evidence in Hepatitis C Virus: A systematic review. Pharmacoeconomics 2020;38:927-39. [PMID: 32533524 DOI: 10.1007/s40273-020-00933-3] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]